|
Gemtuzumab ozogamicin
resources
|
|
|
|
|
|
DRUG INFO
Gemtuzumab ozogamicin
Drug Name:
Gemtuzumab ozogamicin
Indication: For treatment of acute myeloid leukemia
Pharmacology: Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cells.
Mechanism Of Action: Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death.
Drug Category: Antineoplastic Agents
Brand Names/Synonyms: Mylotarg; anti-CD33; Mylotarg (Wyeth)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Humanized chimeric anti-CD33 antibody
Chemical Formula: Not Available
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00077
CAS Registry Number: 220578-59-6
|
|
|
|
|
|
Gemtuzumab ozogamicin News
(When available)
PDL Grants Patent Licenses to Merck for Humanized Antibodies ... Jan 3, 2006
Yahoo! News (press release) ...(Synagis®); Roche (Zenapax®); and Wyeth (Mylotarg®). ... Synagis is a registered US trademark of MedImmune, Inc. Mylotarg is a registered US trademark of Wyeth.
PDL Grants Patent Licenses to Merck for Humanized Antibodies ... Jan 3, 2006
PR Newswire (press release), Inc. (Synagis(R)); Roche (Zenapax(R)); and Wyeth (Mylotarg(R)). Further information on PDL is available at http://www.pdl.com . ...
|
|
|
